Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ramiro Garzon

Showing results (81-90 of 134) with videos related to

Pageof 14
Sort By:
Oncotarget|July 23, 2016
MicroRNA fingerprints in juvenile myelomonocytic leukemia (JMML) identified miR-150-5p as a tumor suppressor and potential target for treatmentPier Paolo Leoncini, Alice Bertaina, Dimitrios Papaioannou, et al.
The AAPS Journal|November 27, 2012
In vivo quantification of active decitabine-triphosphate metabolite: a novel pharmacoanalytical endpoint for optimization of hypomethylating therapy in acute myeloid leukemiaHongyan Wang, Ping Chen, Jiang Wang, et al.
Cancer Discovery|June 30, 2016
Dissection of the Major Hematopoietic Quantitative Trait Locus in Chromosome 6q23.3 Identifies miR-3662 as a Player in Hematopoiesis and Acute Myeloid LeukemiaSophia E Maharry, Christopher J Walker, Sandya Liyanarachchi, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 1, 2008
Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosminRamiro Garzon, Michela Garofalo, Maria Paola Martelli, et al.
International Journal of Hematologic Oncology|October 5, 2020
Incidence of venous thrombosis after peg-asparaginase in adolescent and young adults with acute lymphoblastic leukemiaBrynne Underwood, Qiuhong Zhao, Alison R Walker, et al.
Blood|May 5, 2017
Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphomaJohn Kuruvilla, Michael Savona, Rachid Baz, et al.
Blood|March 25, 2017
A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemiaRamiro Garzon, Michael Savona, Rachid Baz, et al.
Leukemia & Lymphoma|September 4, 2023
Phase 1 study of selinexor in combination with salvage chemotherapy in Adults with relapsed or refractory Acute myeloid leukemiaBhavana Bhatnagar, Qiuhong Zhao, Alice S Mims, et al.
Haematologica|August 16, 2019
Mutations associated with a 17-gene leukemia stem cell score and the score's prognostic relevance in the context of the European LeukemiaNet classification of acute myeloid leukemiaMarius Bill, Deedra Nicolet, Jessica Kohlschmidt, et al.
American Journal of Hematology|August 11, 2020
A phase I study of lenalidomide plus chemotherapy with idarubicin and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromeCaner Saygin, Karilyn Larkin, James S Blachly, et al.
Pageof 14

Showing results (81-90 of 134) with videos related to

Sort By:
Pageof 14
Oncotarget|July 23, 2016
MicroRNA fingerprints in juvenile myelomonocytic leukemia (JMML) identified miR-150-5p as a tumor suppressor and potential target for treatmentPier Paolo Leoncini, Alice Bertaina, Dimitrios Papaioannou, et al.
The AAPS Journal|November 27, 2012
In vivo quantification of active decitabine-triphosphate metabolite: a novel pharmacoanalytical endpoint for optimization of hypomethylating therapy in acute myeloid leukemiaHongyan Wang, Ping Chen, Jiang Wang, et al.
Cancer Discovery|June 30, 2016
Dissection of the Major Hematopoietic Quantitative Trait Locus in Chromosome 6q23.3 Identifies miR-3662 as a Player in Hematopoiesis and Acute Myeloid LeukemiaSophia E Maharry, Christopher J Walker, Sandya Liyanarachchi, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 1, 2008
Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosminRamiro Garzon, Michela Garofalo, Maria Paola Martelli, et al.
International Journal of Hematologic Oncology|October 5, 2020
Incidence of venous thrombosis after peg-asparaginase in adolescent and young adults with acute lymphoblastic leukemiaBrynne Underwood, Qiuhong Zhao, Alison R Walker, et al.
Blood|May 5, 2017
Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphomaJohn Kuruvilla, Michael Savona, Rachid Baz, et al.
Blood|March 25, 2017
A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemiaRamiro Garzon, Michael Savona, Rachid Baz, et al.
Leukemia & Lymphoma|September 4, 2023
Phase 1 study of selinexor in combination with salvage chemotherapy in Adults with relapsed or refractory Acute myeloid leukemiaBhavana Bhatnagar, Qiuhong Zhao, Alice S Mims, et al.
Haematologica|August 16, 2019
Mutations associated with a 17-gene leukemia stem cell score and the score's prognostic relevance in the context of the European LeukemiaNet classification of acute myeloid leukemiaMarius Bill, Deedra Nicolet, Jessica Kohlschmidt, et al.
American Journal of Hematology|August 11, 2020
A phase I study of lenalidomide plus chemotherapy with idarubicin and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromeCaner Saygin, Karilyn Larkin, James S Blachly, et al.
Pageof 14